KLK3 and prostate carcinoma: In 1991, the low specificity of PSA for the detection of prostate cancer was improved by the identification of two major molecular subforms of PSA, an unbound proportion (free PSA, fPSA) and a form complexed with the protease inhibitor alpha-1-antichimotrypsin [15].